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Lumbar sympathectomy
No objective evidence supports the use of lumbar
sympathectomy in the treatment of IC.25 Neither rest-
ing nor exercise blood flow is increased by the per-
formance of a syrnpathectomy.e
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B 4.5
Comparison of Therapeutic Options for
Intermittent Claudication
There is overwhelming evidence that walking capaci-
ty is increased by exercise. The timing and type of
exercise has been extensively studied, and supervised
frequent exercise sessions offer significant benefit in
increasing claudication distance (see B 4.1.2, Basic
Treatment, p 568).1 The question as to whether exercise
is superior to limited interventions such as balloon
angioplasty (PTA) is more controversial. In a study
from the United Kingdom, in which patients were fol-
lowed-up for 6 years, ABPI increased during the first
15 months after PTA; however, more significant
changes in walking distances were seen in the exercise
group. At 6 years' follow-up, there were no differences
between groups- (see also Recommendation 29, p
573). The loss of the initial advantage of PTA was
attributable to restenosis of the dilated segment,
whereas those treated conservatively had a steadily
increasing benefit of exercise. The later loss of advan-
tage of exercise was probably due to lack of adherence
to the exercise program. The best effect of exercise was
found in patients with disease confined to the superfi-
cial femoral artery, in contrast to PTA, which has the
best effect in iliac lesions.
In a second British study screening 600 patients
with Ie during follow-up of 6 months, PTA patients
benefited more in walking distance and ABPI than
those randomised to exercise.' The report on quality of
life recorded a better response after PTA than after
exercise. However, when the same group reported
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their results after 2 years' follow-up, there were no sig-
nificant differences in patient-reported walking dis-
tances, exercise treadmill distances (to onset of pain or
maximal distance), ABPI, or quality of life.' Only the
number of patent arteries favoured PTA. Thus, two
randomised trials with extended follow-up showed
no advantage to PTA. However, in these two trials, the
predominant lesions were in the femoropopliteal seg-
ment, not the iliac arteries, where PTA results are
much better (over 20% better patency).
Another study has shown that III/supervised exercise
programs are unlikely to significantly improve the
patient's quality of life compared with interventional
treatment.f Using the McMaster Health Index
Questionnaire, an Italian study showed that the quali-
ty of life was impaired in patients suffering from IC;
however, this impairment correlated poorly to the
reduced exercise capacitye A randomised study com-
pared percutaneous transluminal angioplasty (n = 20)
with a supervised program of dynamic leg exercises (n
= 16).7 Constant-load treadmill testing was performed
at 3, 6, 9, and 12 months to evaluate change in pain-
free and maximal walking distances. It was found
that, after angioplasty, mean ABPI were significantly
improved, but only at the 3-month point was maxi-
mum walking distance improved over baseline. In
contrast, in the exercise group, despite no improve-
ment in the ABPI, maximal and pain-free walking dis-
tances were progressively increased at each follow-up,
with significant increases at 6, 9, and 12 months. For
example, pain-free walking distance increased by
296% and maximum walking distance by 442% at the
12-month point in the exercise-trained group.
Care must be taken when reviewing reports of com-
parative trials of PTA. Many studies report the results
of the treatment of the most favourable lesions, and
these may not always be extrapolated to all lesions in
a similar area. The breadth of vascular disease fre-
quently makes comparative study groups less than
equal. The results of PTA are frequently reported for
claudicators, whereas surgical results often include
patients with CLI. These facts must be remembered
when reviewing the literature and choosing the best
treatment for an individual patient. Calls for appro-
priate long-term randomised control trials have been
made." Such studies should include assessment of
both walking distance and quality of life.
A further question is whether there is a functional
benefit of surgery in patients with K'. In a study pre-
sented in 1993, it was found that after 6 weeks there
was an improvement in resting ABPI, as well as of
treadmill walking time and of self-reported communi-
ty-based walking ability? Another study evaluating
functional outcome included 68% inflow procedures,
with the remaining being infrainguinal operations, of
which 93% were femoropopliteal bypass grafts. It was
found that the procedure gave optimal results if
restricted to patients younger than 70 years, who were
nondiabetic patients, and in those in whom a normal-
isation of the ankle pressure could be anticipated.w
Interestingly, when functional status was assessed
postrevascularisation, this study showed that 17% of
patients were dissatisfied with their outcome. Of
these, approximately 50% had a normal postoperative
ABPI. This implies that surgical morbidity, even with-
out complications, is important in patient satisfac-
tion-independent of the success of the revascularisa-
tion.
Lundgren et al" conducted a randomised, con-
trolled trial comparing the effects of (1) peripheral
bypass surgery alone; (2) surgery followed by 6
months of supervised exercise training with dynamic
leg exercises; and (3) 6 months of supervised exercise
training alone in 75 patients with claudication.
Constant-load treadmill testing was used in this study.
At 13 months after randomisation, walking ability was
improved in all three groups. In this study, the most
effective treatment for improving functional status
was exercise training plus surgery. The changes in
maximal walking distance were 173% for the operated
group, 263% for the group that received both thera-
pies, and 151% for the exercise-trained group. The
authors found that although all surgically treated
patients increased their walking distance more than
patients who received only exercise training, they also
had a greater rate of complications than the exercise
group.
In another study, surgery was compared with PTA.12
This study included not only patients with IC, but also
a small proportion of patients with severe ischaemia.
This randomised, controlled trial was not able to show
a significant difference between bypass surgery and
angioplasty, but, given the sample size, it has only a
power of 0.21 to detect a difference of 50%. For detect-
ing differences in subgroups, the power was even
lower. Furthermore, only patients who were consid-
ered to have lesions appropriate for PTA were entered
in this trial. Today, these cases would not be consid-
ered candidates for surgery but rather would be
referred for PTA. The L-year result of PTA versus sur-
gery was also evaluated in 102 patients over a 6-year
period.P It was found that only 5% of the patients
screened for the study were suitable for both kinds of
treatments and could therefore be included. Thus,
these were almost all patients that today would be
considered for PTA as primary invasive treatment.
The success and complication rates were the same in
both groups, but the hospital stay was significantly
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shorter for the PTA patients. This points out the diffi-
culties in conducting a randomised control trial com-
paring two modalities that are suited for quite differ-
ent lesions.
The most important femoropopliteal study is a deci-
sion and cost-effectiveness analysis of revascularisa-
lion procedures for femoropopliteal disease by
Hunink and colleagues.'! The authors used a literature
review of mortality, morbidity, patency, and cost data
as a source. There were 4,800 PTAs and 4,511 bypass
operations. They developed a decision analytic model
to examine the choice between bypass surgery and
PTA for lesions amenable to either procedure.
Outcomes measured included 5-year patency, QALY,
lifetime costs, and incremental cost-effectiveness
ratios. Six treatment strategies were analysed: (1) no
treatment; (2) initial PTA with no further revasculari-
sation; (3) initial PTA with subsequent PTA; (4) initial
PTA with subsequent bypass surgery; (5) bypass sur-
gery followed by no further therapy; (6) bypass sur-
gery followed by graft revision. The results showed
that for a 65-year-old man with disabling claudication
and a femoropopliteal stenosis or occlusion, the initial
PTA strategy increased QALY by 2 to 13 months and
resulted in decreased lifetime expenditures as com-
pared with bypass surgery. Sensitivity analysis
showed that when the 5-year patency of PTA exceeds
30%, PTA is the preferred initial invasive strategy. The
authors concluded that PTA is the preferred initial
strategy in patients with disabling claudication and
femoropopliteal stenosis or occlusion.
To evaluate the results of the various procedures,
reporting standards are important, including opera-
tive morbidity, mortality, and patency figures that do
not exclude initial failures and identify reintervention
as secondary patency," The interpretation of results of
reconstruction is complicated by the mixture of
patients included in the series, which included not
only claudication as an indication, but more frequent-
ly combinations series of severe ischaemia and Ie.
Furthermore, in the comparison of various treatment
modalities, combinations of proximal and distal
reconstruction are described.
Descriptive series of infrainguinal bypass for clau-
dication with a distal anastomosis above the knee, but
including all kinds of autologous or synthetic materi-
als, claim a 5-year patency of 60% to 70%,16,17 It there-
fore could be assumed that a synthetic graft (ePTFE or
glutaraldehyde-treated HUV) perform equally well as
the autologous vein. This has lead to the conclusion
that one could advocate a prosthetic conduit, specifi-
cally PTFE, for an AK reconstruction. IS This is not sup-
ported by other studies, however.i? If the procedure
has to be extended below the knee, the use of autolo-
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gous vein is strongly recommended. 20 It is unfortu-
nate that surgical studies reviewed did not include
exercise therapy as one of the treatment options.
However, the meta-analysis cited will be helpful in
choosing between different forms of interventional
therapy. Although not a comparative study, the meta-
analysis by Hunink et a}21 at least yields patency data
for the procedures performed to relieve Ie caused by
atherosclerosis in the femoropopliteal region (for fur-
other results, see B 4.3 Endovascular Procedures, p 582).
Applied across the board, this treatment strategy of
initial PTA provides quality-of-life and lifetime expen-
diture advantages over a strategy of initial bypass sur-
gery (see also Recommendation 31, 583;
Recommendation 34, p 588).
References
1. Gardner AW, Phoehlman ET. Exercise rehabilitation programs
for the treatment of claudication pain . JAMA 199.5; 274: 975-980.
2. Perkins jMT, Collin J, Creasy TS, Fletcher EWL, Morris PJ.
Exercise training versus angioplasty for stable claudication:
long and medium term results of a prospective, randomized
trial. Eur J Vasc Endovasc Surg 1996; 11: 409-413.
3. Whyman MR, Fowkes FGR, Kerracher EMG, Ruckley CV.
Randomized controlled trial of percutaneous transluminal
angioplasty for intermittent claudication. Eur J Vasc Endovasc
Surg 1996;12: 167-172.
4. Whyman MR, Fowkes FGR, Kerracher EMG. Is intermittent
claudication improved by percutaneous transluminal angie-
plasty? J Vase Surg 1997;26: 551-557.
5. Currie Ie, Wilson YG, Baird RN, Lamont PM. Treatment of
intermittent claudication: the impact on quality of life. Eur J
Vasc Endovasc Surg 1995; 10: 356·361.
6. Barletta G, Perna S, Sabba C, Catalano A, O'Boyle C, Brevetti G.
Quality of life in patients with intermittent claudication: rela-
tionship with laboratory exercise performance. Vase Med 1996;
1: 3-7.
7. Creasy TS, McMillam PJ, Fletcher EWL, Collin J, Morris PJ. Is
percutaneous transluminal angioplasty better than exercise for
claudication? Preliminary results from a prospective random-
ized . Eur J Vase Surg 1990;4: 135·140.
8, Bradbury AW, Ruckley CV. Angioplasty for lower-limb
ischemia: time for randomized control trials. Lancet 1996; 347:
277-278.
9. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR.
Functional benefits of peripheral vascular bypass surgery for
patients with intermittent claudication. Angiology 1993; 44: 1-
10.
10. Zannetti S, L'ltalien GJ, Cambria RP. Functional outcome after
surgical treatment for intermittent claudication. J Vasc Surg
1996;24: 65-73.
11. Lundgren F, Dahllof A, Lundholm K, Schersten T, Volkman R.
Intermittent claudication: surgical reconstruction or physical
training? A prospective randomized trial of treatment efficiency.
Ann Surg 1989;209: 346-355.
12, Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal
angioplasty versus operation for peripheral arteriosclerosis:
report of a prospective randomized trial in a selected group of
patients. j Vasc Surg 1989;9: 1-9.
13. Holm j, Arfvidsson B, [ivegard L, Lundgren F, Lundholm K,
Schersten T, et al. Chronic lower limb Ischemia : a prospective
randomized controlled study comparing the I-year results of
vascular surgery and percutaneous transluminal angioplasty
(PTA). Eur J Vasc Surg 1991;5: 517·522.
Treatment of Intermittent Claudication 8103
14. Hunink MGM, Wong JB, Donaldson MC, Meyerovitz MF, de
Vries J, Harrington DP. Revascularization for femoropopliteal
disease: a decision and cost-effectiveness analysis. JAt\1A 1995;
274: 165-171.
15. The Ad Hoc Committee On Reporting Standards. Society for
Vascular Surgery/North American Chapter. International
Society for Cardio-vascular Surgery: suggested standards for
reports dealing with lower extremity ischemia. J VaseSurg 1986;
4: 80-94.
16. Dalman RL, Taylor LM Jr, Moneta GL, Yeager RA, Porter JM.
Simultaneous operative repair of multilevel lower extremity
occlusive disease. J Vase Surg 199( 13: 211-221.
17. Dalman RL, Taylor LM Jr. Basic data related to infrainguinal
revascula-rization procedures. Ann Vase Surg 1990;4: 309-312.
18. Quinones-Baldrich WJ, Busuttil RW,Baker JD, Baker JD, Vescera
CL, Ahn SS, et al. Is the preferential use of poly-tetrafluoroeth-
ylene grafts for femoropopliteal bypass justified? J Vase Surg
1988;8: 219-228.
19. Londrey GL, Ramsey DE, Hodgson KJ, Barkmeicr LD, Sumner
DS. Infrapopliteal bypass for severe ischemia: comparison of
autogenous vein, composite, and prosthetic grafts. J Vase Surg
1991; 13: 631-636.
20. Veith F], Gupta SK, Ascer E, White-Flores S, Samson RH, Scher
LA, et aI. Six-year prospective multicenter randomized compar-
ison of autologous saphenous vein and expanded poly tetra flu-
oroethylene grafts in infra inguinal arterial reconstructions. J
Vase Surg 1986;3: 104-114.
21. Hunink MGM, Wong JB, Donaldson MC, Meyerovitz MF,
Harrington DP. Patency results of percutaneous and surgical
revascularization for femoropopliteal arterial- disease. Med
Decis Making 1994;14: 71-81.
B 4.6
Management Algorithm for Intermittent Claudication
B 4.6.1
Basic Strategy Algorithm for Intermittent Claudication
I History and physical examination J
Ankle:brachial pressure index
Confirm PAD with intermittent claudication
IIAssess cardiovascular + Assess disability" Irisk factors symptom severity
I I
Initial evaluation: Treadmill and/or:
• Haemoglobin • SF-36 questionnaire
• Serum creatinine • WIQ questionnaire
• Smoking history I
• Lipid profile I I I• Hypertension
• Diabetes IMild symptoms-I Moderate symptoms-« Severe
Not disabled Disabled symptoms-
I I
Disabled
Special investigations: I• Hypercoagulability screen
• Homocysteine level
• Lp(a) Encourage supervised walking exercise program
• Other Consider pharmacotherapy
I.Modify risk factors I I I• Antiplatelet therapy IContinue I
I
Successful Unsuccessful I
F-36 =MedicalOutcomesShort Form 36 Questionnaire outcome outcome
Q =Walking ImpairmentQuestionnaire IVR = pulse volumerecording
= velocitywaveformanalysis Locate lesion using:
=magneticresonanceangiography
• Segmental limb pressuresC = Joint National Commission
• PVRorVWFAIC =haemoglobinAlC
• Duplex scanniogDL = low-densityli~prrtein • AngiographyL =high-density ltOprotein Continue
·MRADisability as defined y the individualpatient noninvasive
measures I
Endovascular or I
surgical therapy
S
WIp
VWF
MRA
IN
Hb
L
lID
•
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